Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Bullboard Posts
Comment by consultant99on Jan 17, 2016 12:12pm
163 Views
Post# 24466364

RE:I will vote for the split....

RE:I will vote for the split....
I read that some would like to have dividend from the cash account...... This is not how to manage a company, dividend must come from revenue and ebit, not from the bank account,


Corporate dividends are paid from after tax cash. There is more than $50 million in after tax cash available. Nuvo should already be profitable based on current US sales and F/X rate.
[Of course unless you actually figure that out yourself you would never know it].

US sales are continuing to grow! Furthermore Nuvo has no exposure to the retail price so if one day Horizan decides to discount P2 to maintain or grow their market share, Nuvo will actually benefit by selling more bottles - thereby increasing supply revenues.

Reducing current operating expenses by shutting down the R & D activities of the company will significantly increase profitability. It will also reduce the parasitic load that management has put on the corporation's finances - no need for two Co-CEOs; not that there ever was.

Revenues will significantly increase with the sale of ex-US marketing rights and the sales of P2 ex-US. As Rock has pointed out the initial dividend will be sustainable and there will be cash available for further investment.

The best to do with this money is what BOD are doing, transfered in a new attractive company that will take time to raise but with some potential,


NO NO NO! That is exactly what the BOD hopes you will think. Management get paid regardless of their performance. The risk around the R & D company will be huge particularly in light of their poor development record, the products they are currently working on and where they are in development.

A dividend is real and it is a return on investment. The Pennsaid 2% business will be all about manufacturing a product which is the least risky part of the drug industry. This business model could be easily sustained  as revenues grow, the dividends increase and the share price rises-not someday but NOW!
Bullboard Posts